Identification of Novel Small Molecule Therapeutics for Visceral Leishmaniasis

Investigator: Adam Renslo, PhD
Sponsor: University of Texas Health Science Center

Location(s): United States


New drugs are needed to treat visceral leishmaniasis (VL) because the current therapies are toxic, expensive, and parasite resistance may weaken drug efficacy. We established a novel ex vivo splenic explant culture system from hamsters infected with luciferase-transfected Leishmania donovani to screen chemical compounds for anti-leishmanial activity.